Week in Review: China Metallurgical Spending $531 Million to Build Two Kuwaiti Hospitals

China Metallurgical Group will invest $531 million to build two hospitals with a total capacity of 600 beds in Kuwait; CSPC Pharma of Shijiazhuang entered two out-licensing partnerships worth up to $201 million in milestones, one for a generic oncology drug and the other for a generic antibiotic; Tianjin Pharma Group closed its $20 million investment in Neuralstem, a US-China CNS biopharma; WuXi PharmaTech participated in the $7 million A round of ApoGen Biotechnologies of Seattle; Suzhou's PegBio partnered with Pfizer to bring a Pfizer clinical-stage type 2 diabetes treatment to China; and Medtronic paid a $17.2 million fine in China for price fixing. More details.... Stock Symbols: (HK: 1093) (NSDQ: CUR) (NYSE: PFE) (NYSE: MDT) Share this with colleagues: // //